Study of OSI-211 vs. Topotecan in Patients With Relapsed Epithelial Ovarian Cancer
- Conditions
- Ovarian Neoplasms
- Registration Number
- NCT00046800
- Lead Sponsor
- Astellas Pharma Inc
- Brief Summary
The purpose of this study is to estimate the efficacy and safety of OSI-211 and topotecan in patients with relapsed epithelial ovarian cancer.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 80
- Confirmed relapsed ovarian cancer.
- Measurable disease greater than or equal to 20 mm (or greater than or equal to 10 mm on spiral CT scan).
- One or two prior regimens of chemotherapy. At least one regimen must have contained cisplatin or carboplatin.
- At least three weeks since prior chemotherapy and recovery from any related toxicities.
- At least four weeks since prior radiotherapy and recovery from any related toxicities.
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (11)
The Sarah Cannon Cancer Center, Centennial Medical Center
🇺🇸Nashville, Tennessee, United States
NYU- Kaplan Comprehensive Cancer Center
🇺🇸New York, New York, United States
St Chad's Unit
🇬🇧Birmingham, United Kingdom
Medical Oncology Unit, Torbay District General Hospital
🇬🇧Torquay, United Kingdom
Beatson Oncology Centre
🇬🇧Glasgow, United Kingdom
CRC Department of Medical Oncology
🇬🇧Sutton Surrey, United Kingdom
Royal Surrey County Hospital
🇬🇧Guildford, Surrey, United Kingdom
Taunton & Somerset Hospital
🇬🇧Taunton, United Kingdom
Northern Centre for Cancer Research, Newcastle General Hospital
🇬🇧Newcastle-upon-Tyne, United Kingdom
Mount Vernon Hospital
🇬🇧Northwood, Middlesex, United Kingdom
Royal Marsden NHS Trust
🇬🇧London, United Kingdom